Unexpected Response to Nivolumab in a “Fast Progressor” Head and Neck Cancer Patient

Prior to the advent of immune checkpoint inhibitors targeting PD-1/PD-L1 axis no drug demonstrated to improve survival or quality of life in the second-line treatment of recurrent or metastatic head and neck squamous cell carcinoma (R/M-HNSCC). Nivolumab appear to have a clear clinical benefit for R...

Descripción completa

Detalles Bibliográficos
Autores principales: Napolitano, Martina, Trudu, Lucia, Bertolini, Federica
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2019
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6787422/
https://www.ncbi.nlm.nih.gov/pubmed/31607888
http://dx.doi.org/10.1159/000502858

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6787422/
https://www.ncbi.nlm.nih.gov/pubmed/31607888
http://dx.doi.org/10.1159/000502858

Ejemplares similares